Basic Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Jun 14, 2018; 24(22): 2381-2391
Published online Jun 14, 2018. doi: 10.3748/wjg.v24.i22.2381
Table 1 Patients characteristics and univariate analysis (n = 428)
Characteristicsn (%)DFS
OS
t/moP valueχ2/Zt/moP valueχ2/Z
Age (median, yr)0.47-0.720.79-0.26
< 60199 (46.5)40.0244.97
≥ 60229 (53.5)37.7244.34
Gender0.42-0.800.56-0.59
Male304 (71.0)37.7443.99
Female124 (29.0)41.3846.23
Bormann type0.0078.580.0070.97
 I33 (7.7)64.2464.21
II189 (44.2)45.9951.15
III200 (46.7)28.4335.78
IV6 (1.4)17.5027.33
Tumor size0.00-6.170.00-5.87
< 5 cm243 (56.8)46.1550.57
≥ 5 cm185 (43.2)29.1236.84
Location0.094.920.223.03
Up90 (21.0)33.1040.62
Middle121 (28.3)39.9845.26
Low217 (50.7)40.4945.96
Tumor histological morphology0.262.700.362.03
Adenocarcinoma319 (74.5)39.4545.15
Absolute signet ring cell carcinoma3 (0.7)63.6763.67
Mixed carcinoma106 (24.8)36.0942.56
Lauren type0.075.280.065.50
Intestinal200 (49.5)41.7447.59
Diffuse129 (26.9)39.2844.97
Mixed type99 (23.1)33.9640.12
Tumor differentiation0.01-2.740.01-2.54
Poor288 (67.3)36.5442.72
Moderate and high140 (32.7)43.4348.58
Vessel invasion0.00-6.060.00-5.65
No299 (69.9)43.2448.60
Yes129 (30.1)28.4935.47
Perineural invasion0.00-5.630.00-5.26
No320 (74.8)42.7647.95
Yes108 (25.2)27.0334.82
T category0.00143.150.00124.25
T185 (19.9)65.1565.20
T224 (5.6)61.1362.44
T316 (3.7)59.0461.33
T4303 (70.8)28.6136.61
N category0.00323.310.00322.11
N0179 (41.8)62.2063.47
N167 (15.7)37.2248.52
N284 (19.6)23.4833.05
N398 (22.9)10.2417.52
TNM stage0.00285.220.00271.25
 I93 (21.7)64.1664.20
II101 (23.6)63.2765.59
III228 (53.3)18.4428.30
IV6 (1.4)7.009.50
Operation0.00-3.450.00-3.79
D15 (1.2)7.009.20
D2423 (98.8)39.1745.06
Hepatic metastasis0.00-5.310.00-5.10
Yes46 (10.7)18.4828.22
No382 (89.3)41.2446.62
Peritoneum cavity metastasis0.00-14.350.00-13.96
Yes155 (36.2)14.4523.47
No273 (63.8)52.6156.66
HIF-1α0.00-4.410.00-4.24
Weak-expression209 (48.8)44.8049.58
Over- expression219 (51.2)33.0639.92
P4HB0.00-6.880.00-6.91
Weak-expression213 (49.8)48.0352.48
Over- expression215 (50.2)29.6436.87
Table 2 Hypoxia-inducible factor-1α and prolyl 4-hydroxylase beta expressions and clinicopathologic characteristics
CharacteristicsHIF-1α
P4HB
LowHighP valueχ2LowHighP valueχ2
209 (48.8)219 (51.2)213 (49.8)215 (50.2)
Age0.420.650.350.57
< 6093 (46.7)106 (53.3)96 (48.2)103 (51.8)
≥ 60116 (50.7)113 (49.3)117 (51.1)112 (48.9)
Gender0.910.010.480.49
Male149 (49.0)155 (51.0)148 (48.7)156 (51.3)
Female60 (48.4)64 (51.6)65 (52.4)59 (47.6)
Bormann type0.067.260.0029.18
 I16 (48.5)17 (51.5)26 (78.8)7 (21.2)
II104 (55.0)85 (45.0)110 (58.2)79 (41.8)
III88 (44.0)112 (56.0)75 (37.5)125 (62.5)
V1 (16.7)5 (83.3)2 (33.3)4 (66.7)
Tumor size0.301.090.0011.09
< 5 cm124 (51.0)119 (49.0)138 (42.0)110 (58.0)
≥ 5 cm85 (45.9)100 (54.1)75 (14.6)105 (85.4)
Tumor histological morphology0.183.450.491.42
Adenocarcinoma157 (49.2)162 (50.8)163 (51.1)156 (48.9)
Absolute signet ring cell carcinoma3 (100.0)0 (0.0)2 (66.7)1 (33.3)
Mixed carcinoma49 (46.2)57 (53.8)48 (45.3)58 (54.7)
Location0.153.780.630.94
Up40 (14.4)50 (55.6)41 (45.6)49 (54.4)
Middle53 (43.8)68 (56.2)60 (49.6)61 (50.4)
Low116 (53.5)101 (46.5)112 (51.6)105 (48.4)
Lauren type0.055.980.571.14
Intestinal96 (48.0)104 (52.0)104 (52.0)96 (48.0)
Diffuse73 (56.6)56 (43.4)64 (49.6)65 (50.4)
Mixed type40 (40.4)59 (59.6)45 (45.5)54 (54.5)
Tumor differentiation0.083.170.034.53
Poor132 (45.8)156 (54.2)133 (46.2)155 (53.8)
Moderate and high77 (55.0)63 (45.0)80 (57.1)60 (42.9)
Vessel invasion0.211.600.380.78
No152 (50.8)147 (49.2)153 (51.2)146 (48.8)
Yes57 (44.2)72 (55.8)60 (46.5)69 (53.5)
Perineural invasion0.410.690.034.71
No160 (50.0)160 (50.0)169 (52.8)151 (47.2)
Yes49 (45.4)59 (54.6)44 (40.7)92 (59.3)
T category0.0110.930.0044.94
T132 (88.9)4 (11.1)9 (56.3)7 (43.8)
T211 (45.8)13 (54.2)13 (54.2)11 (45.8)
T341 (45.1)50 (54.9)69 (81.2)16 (18.8)
T4125 (45.1)152 (54.9)122 (40.3)181 (59.7)
N category0.0023.550.0054.13
N0111 (62.0)68 (38.0)126 (70.4)53 (29.6)
N128 (41.8)39 (58.2)28 (41.8)39 (58.2)
N237 (44.0)47 (56.028 (33.3)56 (66.7)
N333 (33.7)65 (66.3)31 (31.6)67 (68.4)
TNM stage0.0023.320.0065.64
 I54 (58.1)39 (41.9)72 (77.4)21 (22.6)
II65 (64.4)36 (35.6)65 (64.4)36 (35.6)
III87 (38.2)141 (61.8)75 (32.9)1503 (67.1)
IV3 (50.0)3 (50.0)1 (16.7)5 (83.3)
Operation0.690.160.181.79
D12 (40.0)3 (60.0)1 (20.0)4 (80.0)
D2207 (48.9)216 (51.1)212 (50.1)211 (49.9)
Hepatic metastases0.016.980.073.38
Yes14 (30.4)32 (69.6)17 (37.0)29 (63.0)
No195 (51.0)187 (49.0)196 (51.3)186 (48.7)
Peritoneum cavity metastasis0.0012.670.0039.29
Yes58 (37.4)97 (62.6)46 (29.7)109 (70.3)
No151 (55.3)122 (44.7)167 (61.2)106 (38.8)
Table 3 Multivariate analysis of significant prognostic factor for survival in gastric cancer patients
VariablesDFS
OS
P valueHR95%CIP valueHR95%CI
Bormann0.261.150.91-1.460.381.110.88-1.40
Tumor Size0.340.880.67-1.150.380.890.68-1.16
Tumor differentiation0.950.990.74-1.330.841.030.77-1.31
Vessel invasion0.010.700.53-0.930.190.830.63-1.09
Perineural invasion0.440.900.68-1.190.250.860.66-1.11
TNM stage0.0024.6516.04-37.870.0087.7241.21-186.68
HIF-1α expression0.000.670.52-0.880.000.650.50-0.85
P4HB expression0.040.760.58-1.000.650.940.72-1.23